OpenAlex
PricingAboutJobs
Log inGet started
Work

Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors

HTML

Year: 2017
Type: article
Source: Clinical Cancer Research
DOI: 10.1158/1078-0432.ccr-16-0021
Authors: Roz Brant, Alan Sharpe, Tom Liptrot, Jonathan R. Dry, Elizabeth A. Harrington, J. Carl Barrett, Nicky Whalley, Christopher Womack, Paul Smith, Darren R. Hodgson
Institutions: AstraZeneca (United Kingdom), The Christie Hospital, The Christie NHS Foundation Trust, AstraZeneca (United States)
Language: English

Topic: Lung Cancer Treatments and Mutations
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: MEK inhibitors, Ras/ERK pathway, non-small cell lung cancer, gene expression signatures, NanoString, KRAS mutation, predictive biomarkers, formalin-fixed paraffin-embedded tissue, patient selection for targeted therapy
SDG: Good health and well-being

Open Access status: closed

Funder: AstraZeneca
OpenAlex ID: W2530771314
FWCI: 3.197
Cites: 32
Cited by: 32
Related to: 9
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security